Stock News

Entellus Medical, Inc. (ENTL) EPS Estimated At $-0.45; Autodesk (ADSK) Shorts Increased By 12.69%

Autodesk Incorporated (NASDAQ:ADSK) had an increase of 12.69% in short interest. ADSK’s SI was 5.27M shares in February as released by FINRA. Its up 12.69% from 4.68M shares previously. With 4.43M avg volume, 1 days are for Autodesk Incorporated (NASDAQ:ADSK)’s short sellers to cover ADSK’s short positions. The SI to Autodesk Incorporated’s float is 2.52%. The stock increased 0.52% or $0.6 during the last trading session, reaching $115.62. About 1.12 million shares traded. Autodesk, Inc. (NASDAQ:ADSK) has risen 91.08% since February 1, 2017 and is uptrending. It has outperformed by 74.38% the S&P500.

Analysts expect Entellus Medical, Inc. (NASDAQ:ENTL) to report $-0.45 EPS on February, 20.They anticipate $0.06 EPS change or 15.38% from last quarter’s $-0.39 EPS. After having $-0.49 EPS previously, Entellus Medical, Inc.’s analysts see -8.16% EPS growth. The stock increased 0.08% or $0.02 during the last trading session, reaching $24.05. About 55,244 shares traded. Entellus Medical, Inc. (NASDAQ:ENTL) has declined 17.59% since February 1, 2017 and is downtrending. It has underperformed by 34.29% the S&P500.

Since August 28, 2017, it had 0 insider buys, and 5 insider sales for $6.74 million activity. $1.02M worth of Autodesk, Inc. (NASDAQ:ADSK) was sold by Blum Steven M on Friday, September 22. $169,230 worth of Autodesk, Inc. (NASDAQ:ADSK) shares were sold by BEVERIDGE CRAWFORD W. 24,004 shares valued at $2.71 million were sold by Anagnost Andrew on Monday, August 28. Di Fronzo Pascal W sold $64,328 worth of stock. NORRINGTON LORRIE M sold $2.78M worth of Autodesk, Inc. (NASDAQ:ADSK) on Thursday, September 28.

Autodesk, Inc. operates as a design software and services firm worldwide. The company has market cap of $25.47 billion. It operates through Architecture, Engineering, and Construction; Manufacturing; Platform Solutions and Emerging Business; and Media and Entertainment divisions. It currently has negative earnings. The firm offers AutoCAD, a professional design, drafting, detailing, and visualization software; and AutoCAD LT, a professional drafting and detailing software; Maya and 3ds Max software products that offer 3D modeling, animation, effects, rendering, and compositing solutions; and Revit software for building information modeling.

Among 27 analysts covering Autodesk Inc. (NASDAQ:ADSK), 18 have Buy rating, 3 Sell and 6 Hold. Therefore 67% are positive. Autodesk Inc. had 109 analyst reports since August 4, 2015 according to SRatingsIntel. The stock has “Overweight” rating by Morgan Stanley on Friday, August 25. The firm earned “Underweight” rating on Monday, August 29 by Mitsubishi UFJ. The firm earned “Neutral” rating on Thursday, May 12 by Wedbush. Credit Suisse maintained the shares of ADSK in report on Friday, February 26 with “Outperform” rating. Canaccord Genuity maintained Autodesk, Inc. (NASDAQ:ADSK) rating on Monday, June 19. Canaccord Genuity has “Buy” rating and $12000 target. The stock has “Neutral” rating by UBS on Friday, August 26. The firm earned “Overweight” rating on Wednesday, December 7 by Barclays Capital. Citigroup maintained Autodesk, Inc. (NASDAQ:ADSK) on Monday, August 28 with “Neutral” rating. The stock has “Outperform” rating by Credit Suisse on Monday, August 31. RBC Capital Markets maintained the shares of ADSK in report on Friday, August 19 with “Sector Perform” rating.

Investors sentiment increased to 1.42 in Q3 2017. Its up 0.23, from 1.19 in 2017Q2. It improved, as 36 investors sold Autodesk, Inc. shares while 132 reduced holdings. 61 funds opened positions while 177 raised stakes. 206.38 million shares or 1.05% more from 204.24 million shares in 2017Q2 were reported. Glenmede Na has 3,112 shares for 0% of their portfolio. Eagle Asset Mngmt has invested 0.23% of its portfolio in Autodesk, Inc. (NASDAQ:ADSK). Retirement Sys Of Alabama holds 0.06% or 106,343 shares in its portfolio. Wallington Asset Ltd holds 0.92% or 30,870 shares. Manufacturers Life Insurance The accumulated 355,513 shares or 0.05% of the stock. Mycio Wealth Ptnrs Limited Liability Company reported 2,500 shares stake. Ascend Cap invested in 1.64% or 388,476 shares. Sei Invs Company holds 135,014 shares or 0.05% of its portfolio. Banque Pictet And Cie Sa holds 0.01% or 4,000 shares in its portfolio. Vident Invest Advisory Lc owns 114,102 shares for 0.69% of their portfolio. Huntington Retail Bank has 11,882 shares. Cornerstone Cap Lc holds 0.03% or 37,855 shares. Pointstate Capital Lp has invested 2.12% of its portfolio in Autodesk, Inc. (NASDAQ:ADSK). Sterling Cap Mgmt Ltd Com reported 7,098 shares stake. Farmers And Merchants Invests reported 73 shares.

Entellus Medical, Inc., a medical technology company, focuses on the design, development, and commercialization of products for the minimally invasive treatment of patients suffering from chronic and recurrent sinusitis. The company has market cap of $618.76 million. The firm offers XprESS Multi-Sinus Dilation family of products consisting of XprESS Pro device, XprESS LoProfile device, and XprESS Ultra device, which open an obstructed or narrowed drainage pathway of a sinus cavity by means of trans-nasal balloon sinus dilation. It currently has negative earnings. It also provides PathAssist tools, such as LED Light Fiber, a single-use tool that provides real-time high intensity red trans-illumination of the sinus cavity with its battery power; Light Fiber, a single-use tool that provides real-time trans-illumination of the sinus cavity; Light Seeker, a tool with optical fibers embedded into the device to allow ear, nose, and throat physicians to access the frontal sinus and trans-illuminate the sinus cavity; Maxillary Seeker, a tool that allow users to find the correct angle to access the natural maxillary ostia; and Sphenoid Seeker/Freer, a two-in-one tool that enables ENT physicians to navigate access to the sphenoid ostium.

Among 6 analysts covering Entellus Medical (NASDAQ:ENTL), 4 have Buy rating, 0 Sell and 2 Hold. Therefore 67% are positive. Entellus Medical had 9 analyst reports since August 9, 2015 according to SRatingsIntel. The stock has “Buy” rating by Deutsche Bank on Thursday, October 6. On Monday, August 21 the stock rating was maintained by Piper Jaffray with “Buy”. The company was downgraded on Friday, December 8 by William Blair. The rating was initiated by BTIG Research on Tuesday, June 14 with “Buy”. Canaccord Genuity maintained it with “Buy” rating and $27 target in Sunday, August 9 report. The firm has “” rating by Piper Jaffray given on Tuesday, September 29. The firm earned “Hold” rating on Monday, October 16 by Canaccord Genuity.

Leave a Reply

Your email address will not be published. Required fields are marked *